WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H130155
CAS#: 523983-93-9
Description: T0510-3657 is a selective activator of GPR17, inhibiting cAMP levels, with potential for playing a key role in the development of a treatment against diseases such as, multiple sclerosis, Parkinson disease, Alzheimer's disease, and cancer.
Hodoodo Cat#: H130155
Name: T0510-3657
CAS#: 523983-93-9
Chemical Formula: C30H30F3N5O5S2
Exact Mass: 661.16
Molecular Weight: 661.720
Elemental Analysis: C, 54.45; H, 4.57; F, 8.61; N, 10.58; O, 12.09; S, 9.69
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: T0510-3657; T0510 3657; T0510.3657
IUPAC/Chemical Name: N-(4-isopropylphenyl)-2-((5-(3-(morpholinosulfonyl)phenyl)-4-(4-(trifluoromethoxy)phenyl)-4H-1,2,4-triazol-3-yl)thio)acetamide
InChi Key: UENHMSTYHNSINA-UHFFFAOYSA-N
InChi Code: InChI=1S/C30H30F3N5O5S2/c1-20(2)21-6-8-23(9-7-21)34-27(39)19-44-29-36-35-28(38(29)24-10-12-25(13-11-24)43-30(31,32)33)22-4-3-5-26(18-22)45(40,41)37-14-16-42-17-15-37/h3-13,18,20H,14-17,19H2,1-2H3,(H,34,39)
SMILES Code: O=C(NC1=CC=C(C(C)C)C=C1)CSC2=NN=C(C3=CC=CC(S(=O)(N4CCOCC4)=O)=C3)N2C5=CC=C(OC(F)(F)F)C=C5
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 661.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. Konda Mani S, Thiyagarajan R, Yli-Harja O, Kandhavelu M, Murugesan A. Structural analysis of human G-protein-coupled receptor 17 ligand binding sites. J Cell Biochem. 2023 Feb 15. doi: 10.1002/jcb.30388. Epub ahead of print. PMID: 36791278.
2. Murugesan A, Nguyen P, Ramesh T, Yli-Harja O, Kandhavelu M, Saravanan KM. Molecular modeling and dynamics studies of the synthetic small molecule agonists with GPR17 and P2Y1 receptor. J Biomol Struct Dyn. 2022;40(23):12908-12916. doi: 10.1080/07391102.2021.1977707. Epub 2021 Sep 20. PMID: 34542380.
3. Doan P, Nguyen P, Murugesan A, Candeias NR, Yli-Harja O, Kandhavelu M. Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity. Cells. 2021 Aug 3;10(8):1975. doi: 10.3390/cells10081975. PMID: 34440745; PMCID: PMC8393831.
4. Saravanan KM, Palanivel S, Yli-Harja O, Kandhavelu M. Identification of novel GPR17-agonists by structural bioinformatics and signaling activation. Int J Biol Macromol. 2018 Jan;106:901-907. doi: 10.1016/j.ijbiomac.2017.08.088. Epub 2017 Aug 18. PMID: 28827203.